Praxis Precision Medicines, Inc. (PRAX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Boston, MA, United States. The current CEO is Marcio Silva De'Souza.
PRAX has IPO date of 2020-10-16, 116 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $7.26B.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders caused by neuronal imbalance. The company's lead candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor modulator in Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a T-type calcium channel inhibitor in Phase IIa development for essential tremor. Praxis is also advancing PRAX-562 for severe pediatric epilepsy and adult headache disorders, along with antisense oligonucleotide programs PRAX-222 and KCNT1 targeting genetic forms of epilepsy. Founded in 2015 and headquartered in Boston, Massachusetts, the company has established partnerships with RogCon Inc., Purdue Neuroscience Company, Ionis Pharmaceuticals, and The Florey Institute to support its clinical pipeline.
